HL Financial Services LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 35.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,239 shares of the company’s stock after buying an additional 5,516 shares during the period. HL Financial Services LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $706,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Pictet Asset Management Ltd. raised its position in Teva Pharmaceutical Industries Limited by 0.4% in the second quarter. Pictet Asset Management Ltd. now owns 3,026,485 shares of the company’s stock valued at $84,318,000 after buying an additional 12,397 shares during the period. TD Asset Management Inc. raised its position in Teva Pharmaceutical Industries Limited by 4.6% in the second quarter. TD Asset Management Inc. now owns 2,200,584 shares of the company’s stock valued at $73,104,000 after buying an additional 96,857 shares during the period. Physicians Financial Services Inc. raised its position in Teva Pharmaceutical Industries Limited by 5.2% in the second quarter. Physicians Financial Services Inc. now owns 12,108 shares of the company’s stock valued at $402,000 after buying an additional 600 shares during the period. Cullen Frost Bankers Inc. raised its position in Teva Pharmaceutical Industries Limited by 4.8% in the second quarter. Cullen Frost Bankers Inc. now owns 12,056 shares of the company’s stock valued at $401,000 after buying an additional 555 shares during the period. Finally, WealthTrust Axiom LLC purchased a new position in Teva Pharmaceutical Industries Limited during the second quarter valued at $319,000. 56.27% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.30 on Friday. The firm’s market capitalization is $17.58 billion. The company has a 50-day moving average price of $29.64 and a 200-day moving average price of $31.56. Teva Pharmaceutical Industries Limited has a one year low of $16.81 and a one year high of $55.39.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the prior year, the firm earned $1.25 earnings per share. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be issued a $0.085 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.97%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -18.95%.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/hl-financial-services-llc-purchases-5516-shares-of-teva-pharmaceutical-industries-limited-teva.html.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a report on Wednesday. Deutsche Bank AG reissued a “buy” rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Jefferies Group LLC reissued a “hold” rating and issued a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price target (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Three investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $37.69.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.